Page 37 - Bio Developments News Today

The Oxford-GSK Institute of Molecular and Computational Medicine has been created via a five-year collaboration between GlaxoSmithKline and the University of Oxford.

Sanofi will acquire Origimm Biotechnology GmbH, an Austrian privately-owned biotech developing a therapeutic vaccine for acne.

EverImmune, a biotech based near Paris, and specialized in the development of live biotherapeutic products in the field of microbiota oncology, has raised €5m (US$5.7m) in a Series A funding round from undisclosed private investors.

Chinook Therapeutics, Inc. has announced the formation of SanReno Therapeutics - a joint venture with an investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners China - to develop, manufacture and commercialize kidney disease therapies in China.

Australian biotech EnGeneIC, which is developing its nanocell tech for use in infectious diseases (including a COVID-19 vaccine) as well as a cancer treatment, has announced a deal with US biotech ImmunityBio to develop, manufacture and commercialize the tech.

Moderna, BioNTech and Johnson & Johnson have all started developing Omicron-specific vaccines: among a wider response plan to the SARS-CoV-2 variant.

A new clinical trial of heterologous – or ‘mix-and-match’ – combinations of COVID-19 vaccines is set to start in Pakistan: seeking to add to research on the effectiveness of such combinations.

A centralized testing approach, developed by the Coalition for Epidemic Preparedness Innovations (CEPI) and used by more than 30 COVID-19 vaccine developers, will be expanded to create a standardized evaluation model for other epidemic and pandemic disease threats.

Donaldson Company, Inc., a global provider of filtration products and solutions, has acquired Solaris Biotechnology Srl for around €41m ($46m).

AstraZeneca has built a new R&D facility - The Discovery Centre (DISC) - in Cambridge in the UK.